Baroreflex Activation Therapy in Heart Failure With Reduced Ejection Fraction: Available Data and Future Perspective

被引：11
作者：
Halbach M. [1 ]
Fritz T. [1 ]
Madershahian N. [2 ]
Pfister R. [1 ]
Reuter H. [1 ]
机构：
[1] Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, Cologne
[2] Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Cologne
来源：
Current Heart Failure Reports | 2016年 / 13卷 / 2期
关键词：
Baroreceptors; Baroreflex activation therapy; Carotid sinus stimulation; Heart failure;
D O I：
10.1007/s11897-016-0286-8
中图分类号：
学科分类号：
摘要：
Progression of heart failure with reduced ejection fraction (HFrEF) is promoted by sympathovagal imbalance. Baroreflex activation therapy, i.e., electrical stimulation of baroreceptors at the carotid sinus, can restore sympathovagal balance. Large animal studies of baroreflex activation therapy revealed improvements in cardiac function, susceptibility to ventricular arrhythmias, and a survival benefit as compared to untreated controls. Recently, the first randomized and controlled trial of optimal medical and device therapy alone or plus baroreflex activation therapy in patients suffering from HFrEF was published. It demonstrated a reasonable safety profile in this severely ill patient population. Moreover, the study found significant improvements in New York Heart Association class, quality of life, 6-min walk distance, and NT-proBNP levels. This review provides an overview on baroreflex activation therapy for the treatment of HFrEF—from the concept and preclinical findings to most recent clinical data and upcoming trials. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：71 / 76
页数：5
相关论文
共 20 条
  • [1] Brunner-La Rocca H.P., Esler M.D., Jennings G.L., Et al., Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure, Eur Heart J, 22, 13, pp. 1136-1143, (2001)
  • [2] Ambrosy A.P., Fonarow G.C., Butler J., Et al., The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries, J Am Coll Cardiol, 63, 12, pp. 1123-1133, (2014)
  • [3] McMurray J.J., Adamopoulos S., Anker S.D., Et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur J Heart Fail, 14, 8, pp. 803-869, (2012)
  • [4] Sabbah H.N., Gupta R.C., Imai M., Et al., Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure, Circ Heart Fail, 4, 1, pp. 65-70, (2011)
  • [5] Sabbah H.N., Baroreflex activation for the treatment of heart failure, Curr Cardiol Rep, 14, 3, pp. 326-333, (2012)
  • [6] Heusser K., Tank J., Engeli S., Et al., Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients, Hypertension, 55, 3, pp. 619-626, (2010)
  • [7] Zucker I.H., Hackley J.F., Cornish K.G., Et al., Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure, Hypertension, 50, 5, pp. 904-910, (2007)
  • [8] Bakris G.L., Nadim M.K., Haller H., Et al., Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial, J Am Soc Hypertens, 6, 2, pp. 152-158, (2012)
  • [9] Victor R.G., Carotid baroreflex activation therapy for resistant hypertension, Nat Rev Cardiol, 12, 8, pp. 451-463, (2015)
  • [10] Gronda E., Seravalle G., Brambilla G., Et al., Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study, Eur J Heart Fail, 16, 9, pp. 977-983, (2014)
12